Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Return on Capital Employed (2018 - 2025)

Denali Therapeutics (DNLI) has disclosed Return on Capital Employed for 8 consecutive years, with 0.55% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed fell 18.0% to 0.55% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.55% through Dec 2025, down 18.0% year-over-year, with the annual reading at 0.48% for FY2025, 6.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.55% at Denali Therapeutics, down from 0.54% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.03% in Q2 2021, with the low at 0.55% in Q4 2025.
  • Average Return on Capital Employed over 5 years is 0.27%, with a median of 0.32% recorded in 2024.
  • The sharpest move saw Return on Capital Employed surged 43bps in 2021, then plummeted -37bps in 2022.
  • Over 5 years, Return on Capital Employed stood at 0.28% in 2021, then dropped by -23bps to 0.35% in 2022, then surged by 49bps to 0.18% in 2023, then plummeted by -111bps to 0.37% in 2024, then tumbled by -49bps to 0.55% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.55%, 0.54%, and 0.47% for Q4 2025, Q3 2025, and Q2 2025 respectively.